COMP <GO>
LQDA vs ARQT // DIVIDEND YIELD & FCF PAYOUT SAFETY
Liquidia Corporation (NASDAQ) VS. Arcutis Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LQDA 3
— ARQT 8
■ METRIC PARITY
LAST: $41.85 (-7.12%) • MKT CAP: $4.03B
dividend-safety
0.00%
LAST: $31.26 (-2.53%) • MKT CAP: $4.03B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LQDA VS. ARQT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LQDA | ARQT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 90.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.60% | -3.00% | -9.60 | ARQT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.99% | -0.16% | -0.83 | ARQT | /fcf-yield <GO> |
| Operating Margin | -32.50% | -3.30% | -29.20 | ARQT | /operating-margins <GO> |
| Net Profit Margin | -43.50% | -4.30% | -39.20 | ARQT | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 91.30% | +88.70 | LQDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.33 | 7.78 | -1.45 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 66.0 | -13.50 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.00 | -0.10 | ARQT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 24.0x | -3.00 | LQDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $4.03B | $2.3M | LQDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LQDA REV | ARQT REV | LQDA GROSS % | ARQT GROSS % | LQDA FCF | ARQT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $158.3M | $376.1M | — | 90.2% | -$40.0M | -$6.3M |
| FY 2024 | $14.0M | $196.5M | 58.0% | 90.3% | -$98.4M | -$112.3M |
| FY 2023 | $17.5M | $59.6M | — | — | -$42.4M | -$249.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LQDA // BETA 0.90
ARQT // BETA 1.00